Trevena
TRVNPhase 3Trevena is an innovative biopharmaceutical company dedicated to delivering groundbreaking medicines to address the critical needs of patients with central nervous system (CNS) disorders.
Market Cap
$10K
Focus
Small Molecules
TRVN · Stock Price
USD 0.01290.61 (-100.00%)
Historical price data
About
Trevena is an innovative biopharmaceutical company dedicated to delivering groundbreaking medicines to address the critical needs of patients with central nervous system (CNS) disorders.
Pipeline Snapshot
1616 drugs in pipeline, 3 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| TRV130 | Acute Pain | Phase 3 |
| Oliceridine + Placebo + Morphine | Acute Pain | Phase 3 |
| Oliceridine + Placebo + Morphine | Acute Pain | Phase 3 |
| TRV130 + Morphine + Placebo | Pain | Phase 2 |
| TRV130 | Pain | Phase 2 |
Company Info
TypePublic
LocationUnited States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile